50377 Factors associated with the initiation of a new systemic therapy among adults with atopic dermatitis: Data from the CorEvitas Atopic Dermatitis Registry
Recommended Citation
Simpson E, Li A, Dawson Z, Ho K, Stein-Gold L, Desai S, Golant A, DiRuggiero D, Silverberg J. 50377 Factors associated with the initiation of a new systemic therapy among adults with atopic dermatitis: Data from the CorEvitas Atopic Dermatitis Registry. J Am Acad Dermatol 2024; 91(3):AB215.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: Given the significant burden of atopic dermatitis (AD) and relative hesitancy of providers to escalate therapy, it is important to recognize when to initiate advanced systemic therapy (ST) to prevent delayed or undertreatment. This study explored factors associated with initiation of ST in a population of systemic-eligible patients with moderate-to-severe AD. Methods: This study included adults (≥18 years) from the CorEvitas AD Registry (2020–2022) with a vIGA-AD™>3 and Eczema Area Severity Index (EASI)>12 at enrollment. Study included two cohorts with patients either newly prescribed ST or not prescribed ST at enrollment. Patients on ST before enrollment were excluded. A multivariable mixed-effects logistic regression model was constructed to estimate adjusted odds ratio (aOR) with 95% confidence intervals (95% CI) for factors associated with ST. Covariates with a significance level >0.10 were dropped, then stepwise backward elimination was performed with variable elimination set at significance level of 0.10. Results: Study included patients who were newly prescribed ST (n=673; mean age=50.7 years; 55.6% female) and non-ST (n=229; 47.8 years; 51.3%). Initiation of ST was associated with facial pallor (aOR [95% CI]: 5.7 [1.50–21.71], p=0.01), peak pruritus (1.1 [1.04–1.27], p=0.01), and WPAI (1.01 [1.01–1.03], p<0.001), inversely associated with SCORAD (0.90 [0.82–0.99], p=0.04) and history of biologics (0.06 [0.03–0.16], p<0.001) and not associated with worst fatigue (0.9 [0.84–1.01], p=0.07). Conclusion: The decision to prescribe ST is multifactorial in systemic-eligible patients; however, understanding how these factors may influence treatment is needed to improve care of patients with AD.
Volume
91
Issue
3
First Page
AB215
